Belite Bio Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Belite Bio de 60.6% y 66% respectivamente, mientras que el BPA crecerá en un 59.5% al año.

Información clave

60.6%

Tasa de crecimiento de los beneficios

59.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	24.3%
Tasa de crecimiento de los ingresos	66.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	10 Jul 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

Jul 03

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:BLTE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	32	-19	-10	N/A	3
12/31/2025	10	-26	-30	N/A	5
12/31/2024	N/A	-31	N/A	N/A	5
3/31/2024	N/A	-33	N/A	N/A	N/A
12/31/2023	N/A	-32	-30	-30	N/A
9/30/2023	N/A	-31	N/A	N/A	N/A
6/30/2023	N/A	-23	N/A	N/A	N/A
3/31/2023	N/A	-18	N/A	N/A	N/A
12/31/2022	N/A	-13	-12	-11	N/A
9/30/2022	N/A	-8	N/A	N/A	N/A
6/30/2022	N/A	-8	N/A	N/A	N/A
3/31/2022	N/A	-8	N/A	N/A	N/A
12/31/2021	N/A	-10	-8	-7	N/A
9/30/2021	N/A	-9	N/A	N/A	N/A
6/30/2021	N/A	-8	-7	-7	N/A
3/31/2021	N/A	-7	-6	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BLTE siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BLTE siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BLTE siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (66% al año) de BLTE crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (66% al año) de BLTE crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BLTE se prevé que sea elevada dentro de 3 años.

Belite Bio Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 21% to US$45.67

Recent updates

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

CFO & Director notifies of intention to sell stock

Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $24.999964 million.

Director notifies of intention to sell stock

Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Chief Scientific Officer notifies of intention to sell stock

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

CFO & Director notifies of intention to sell stock

Director notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

New minor risk - Shareholder dilution

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

New major risk - Share price stability

Price target decreased by 21% to US$45.67

Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga

Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease

Belite Bio, Inc to Report Q1, 2023 Results on May 10, 2023

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

Less than half of directors are independent

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Belite Bio, Inc Presents 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease At AAO Annual Meeting 2022

Belite Bio Receives Approval of Lbs-008 Phase 3 Clinical Trial in China

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of Lbs-008 in Stargardt Disease in the U.S

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Belite Bio, Inc to Report Q2, 2022 Results on Aug 10, 2022

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite Bio, Inc Submits Investigational New Drug Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Belite Bio, Inc Presents Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Belite Bio Receives FDA Fast Track Designation For LBS-008

No independent directors

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento